Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of secutrelvir in high-risk outpatients with COVID-19
jRCT2071260072Phase 3Recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Aug 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing secutrelvir with placebo (2 arms). Primary endpoint: Composite clinical outcome through day 28. Started Aug 2026; status: recruiting.
02
Drugs
secutrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2071260072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260072.